Regulated information
Waregem (Belgium)/Rotterdam (The Netherlands)1, 12 July 2016
Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.
Notification of Alychlo NV and Marc Coucke, received on 7 July 2016
-
On 7 July 2016, Fagron received a notification that the shareholding of Alychlo NV and Marc Coucke, a parent undertaking or a controlling person, had crossed the disclosure threshold of 15% on 7 July 2016 as the result of the acquisition of voting securities or voting rights.
-
On the notification date, Alychlo NV and Marc Coucke held a total of 10,838,384 voting rights. 10,831,337 voting rights were held by Alychlo NV and 7,047 voting rights were held by Marc Coucke.
-
Based on the denominator of 71,843,904 (total number of voting rights), in total Alychlo NV and Marc Coucke held on the notification date 15.09% of the total number of voting rights.
-
Alychlo NV is controlled by Marc Coucke.
-
The notification of Alychlo NV and Marc Coucke can be viewed on investors.fagron.com via this link.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
For more information:
Constantijn van Rietschoten
Chief Marketing Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
1 This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release: